로딩 중…
지수 로딩 중…
MedPacto, Inc.
235980· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩3,360-1.61%
2026-06-19
Price Chart
MedPacto, Inc.-13.85%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 115.16B KRW |
| Revenue | 4.79B KRW |
| Net Income | -13.21B KRW |
| Total Assets | 45.36B KRW |
| Net Assets | 42.58B KRW |
| Employees | 57 |
| Value | |
| P/B | 2.70x |
| P/S | 24.07x |
| FCF Yield | -11.71% |
| Profitability | |
| ROE | -31.03% |
| ROA | -29.13% |
| Op. Margin | -300.77% |
| Revenue Growth | 206.20% |
| Financial Health | |
| Debt Ratio | 106.53% |
| Total Debt | 0 KRW |
| FCF | -13.48B KRW |
| Cash | 8.82B KRW |
| Current Ratio | 26.54x |
| Performance | |
| 1Y Return | -13.85% |
| 1M Return | -16.00% |
| From 52W High | -61.16% |
| 1Y MDD | -61.18% |
| Trading | |
| Volume | 164,127 shares |
| Foreign Own. | 4.38% |
| Per Share | |
| EPS | -385 KRW |
| BPS | 1,242 KRW |
Company Info
The company, a bio company that spun off from Theragen Etex in 2013, was listed on the KOSDAQ market in 2019 as a technology growth company. It develops innovative new drugs for treating intractable cancer and chronic diseases, and discovers new drug candidate targets using advanced genome analysis technologies like next-generation sequencing and bioinformatics. Its flagship Baektoseoptip is under co-development for combination therapy with MSD and AstraZeneca. The company pursues precision medicine innovation with customized therapeutics and MA-B2 target antibody therapeutics. MedPacto, established in 2013, is headquartered in Seocho District, Seoul Metropolitan City.